Skip to Main Content

Paper Details

T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy.
J Clin Invest
98
2019
-engineered T cells, FADD, FASLG, Fas, Fas DNR, Fas DNR-engineered T cells, Fas variants, Fas-competent T cells, FasL, T cell, T cell receptor, T cells, apoptosis-inducing ligand, cancer, chimeric antigen receptor, human, malignancies, patient, patient-derived T cells, solid and hematologic cancers, tumor
Author NameAffiliation
Tori N YamamotoCenter for Cancer Research and.
Tori N YamamotoCenter for Cell-Based Therapy, National Cancer Institute (NCI)
Tori N YamamotoUniversity of Pennsylvania
Zhiya YuCenter for Cancer Research and.
Zhiya YuCenter for Cell-Based Therapy, National Cancer Institute (NCI)
Zhiya YuCenter for Cancer Research and.
Zhiya YuCenter for Cell-Based Therapy, National Cancer Institute (NCI)
Bülent Arman AksoyMedical University of South Carolina
Nicholas P RestifoCenter for Cancer Research and.
Nicholas P RestifoCenter for Cell-Based Therapy, National Cancer Institute (NCI)
Nicholas P RestifoUniversity of Pennsylvania
Nicholas P RestifoCenter for Cancer Research and.
Nicholas P RestifoCenter for Cell-Based Therapy, National Cancer Institute (NCI)
Nicholas P RestifoUniversity of Pennsylvania
  • 1 - 14

Datasets

Release 1.2